
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+2
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 24 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address...
Gene editing,life sciences,oncology,t-cell therapies,genome engineering,allogeneic,and off-the-shef cart therapies
Cellectis operates in the Biotechnology research industry.
Cellectis's revenue is 11m - 100m
Cellectis has 201 - 500 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.